Neuroanatomy

H. Joseph Yost, Ph.D. Appointed Senior Vice Provost for Research

Retrieved on: 
火曜日, 4月 23, 2024
American Heart, Society, University, Catholic University of America, Neuroanatomy, Creighton University, Genetics, The, Kabuki syndrome, Mouse, Catholic Church, Cell biology, Postdoctoral researcher, Mentorship, AAAS, Teaching, Neuroscience, Xenopus, Pediatrics, Developmental Biology (journal), Advancement, Research, R2, CHD, Zebrafish, Knowledge, Embryology, Public policy, Ventricular septal defect, Catholic higher education, IPSC, Faculty, National Science Board, Biology, Student, Biotechnology, Nursing

Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.

Key Points: 
  • Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.
  • Yost is coming to Catholic University from the University of Utah School of Medicine bringing more than three decades of teaching and research experience.
  • He is currently the Richard L. Stimson presidential endowed chair, vice chairman for basic science research in the department of pediatrics, and professor of neurobiology and anatomy.
  • “I am honored and deeply grateful for the opportunity to help build The Catholic University of America to a top tier research university.

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

Retrieved on: 
火曜日, 10月 31, 2023
Genomics, University of California, Irvine Medical Center, Stanford University, CONVERGE, Neuro, Hallucination, Neuroanatomy, Deficit spending, Research, University, Artificial intelligence, Weill Cornell Medicine, Drug discovery, Partnership, DSM-IV codes, Delusion, Cornell University, Patient, Diagnosis, SAN, Pharmaceutical industry, Medical device, Schizophrenia, Biotechnology

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.
  • By combining their respective strengths and resources, Verge Genomics and the Pritzker Consortium aim to make substantial strides in the field of schizophrenia research.
  • "We are thrilled to embark on this transformative journey alongside Verge Genomics, combining their AI-powered CONVERGE platform with the invaluable resources of the Pritzker Neuropsychiatric Disorders Research Consortium.
  • This includes the Pritzker Brain Bank, known for stringent subject selection and comprehensive metadata, coupled with deep expertise in human structural and functional neuroanatomy,” said Richard M. Myers, Ph.D., Co-Project Leader, Pritzker Neuropsychiatric Disorders Research Consortium.

Projects launch to map brain connections in mouse and macaque

Retrieved on: 
火曜日, 9月 26, 2023
Electron, Neuron, Dendrite, BRAIN, Eye, Finger, Initiative, TEM, Brain, Gene expression, Cell, RNA, Bangladesh Technical Education Board, Associate, Assistant, Allen Institute, Soma, Animal, Map, Motivation, Axon, Automation, Medical imaging, Microscope, Mobile phone, Neuroanatomy

SEATTLE, Sept. 26, 2023 /PRNewswire/ -- A complete map of all the connections in an entire mammalian brain may be in sight. Allen Institute researchers have just launched three new projects to construct large, detailed maps of neuronal connections in sections of the mouse and macaque brains, with an eye toward creating full wiring diagrams of these animals' brains in the future. These projects are funded by the National Institutes of Health's Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative.

Key Points: 
  • SEATTLE, Sept. 26, 2023 /PRNewswire/ -- A complete map of all the connections in an entire mammalian brain may be in sight.
  • These projects are funded by the National Institutes of Health's Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative .
  • The goal will be to use this pipeline to image an entire hemisphere of a mouse brain at 120 nanometer resolution and the cortical basal ganglia thalamic loop (up to 10 mm3) in very fine detail to better understand how the mouse brain functions.
  • "We can actually map the whole macaque brain in a few years instead of 100 years.

Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial

Retrieved on: 
火曜日, 9月 19, 2023
Osteoarthritis, University, Saol, Pharmacokinetics, COMPASS, Physical medicine and rehabilitation, Associate, Rehabilitation, RAISE, Neuroanatomy, MD, Patient, Phase, Therapy, Chronic pain, Safety, Knee, Birth control, Pharmaceutical industry, Nursing

ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 19, 2023 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that enrollment has been completed in the company's two Phase II trials for SL-1002. 

Key Points: 
  • Topline data for the COMPASS Osteoarthritis Knee Pain Trial will be available in the first quarter of 2024, with topline data from the RAISE Limb Spasticity Trial available shortly thereafter.
  • Topline data for the COMPASS Osteoarthritis Knee Pain Trial will be available in the first quarter of 2024.
  • Both the COMPASS Osteoarthritis Knee Pain Trial ( NCT05470608 ) and the RAISE Limb Spasticity Trial ( NCT05311215 ) are each fully enrolled, at 132 patients and 32 patients, respectively.
  • Saol Therapeutics currently expects topline results for the COMPASS Osteoarthritis Knee Pain Trial in the first quarter of 2024, and the RAISE Limb Spasticity Trial in the second quarter of 2024.

European Wellness and Heidelberg University Revolutionize Down Syndrome Research, Moving into Neurodevelopmental and Neurodegenerative Studies

Retrieved on: 
火曜日, 9月 5, 2023
Neuropsychology, Therapy, Frontiers, MD, EWA, Medicine, BWA, Quality of life, Immunomodulation, Rehabilitation, Research, Heidelberg University Faculty of Law, Language, International trade, Down syndrome, MRI, DSM-IV codes, Cell biology, Heidelberg University, Economic development, Spectrum, Heidelberg, Brain and Behavior, Growth, CPD, Medical device, Pharmaceutical industry, Neuroscience, DS, Neuroanatomy, Brain, Behavior, Anatomy

The studies promise a paradigm shift in developing personalized rehabilitation strategies and care programs.

Key Points: 
  • The studies promise a paradigm shift in developing personalized rehabilitation strategies and care programs.
  • "Individualized assessment of neuroanatomical landmarks and cognitive skills is paramount for developing effective intervention strategies," commented Heidelberg University's Head of Neuroanatomy, Prof. Dr. Thomas Skutella.
  • Established in 1386, Heidelberg University is Germany's oldest university and a renowned research powerhouse in Stem Cell Research & Immunology in Europe.
  • With 56 Nobel Laureates associated with the institution, Heidelberg University boasts an illustrious history.

European Wellness and Heidelberg University Revolutionize Down Syndrome Research, Moving into Neurodevelopmental and Neurodegenerative Studies

Retrieved on: 
火曜日, 9月 5, 2023
Neuropsychology, Therapy, Frontiers, MD, EWA, Medicine, BWA, Quality of life, Immunomodulation, Rehabilitation, Research, Multimedia, Heidelberg University Faculty of Law, Language, International trade, Down syndrome, MRI, DSM-IV codes, Cell biology, Heidelberg University, Economic development, Spectrum, Heidelberg, Brain and Behavior, Growth, CPD, Medical device, Pharmaceutical industry, Neuroscience, DS, Neuroanatomy, Brain, Behavior, Anatomy

The studies promise a paradigm shift in developing personalized rehabilitation strategies and care programs.

Key Points: 
  • The studies promise a paradigm shift in developing personalized rehabilitation strategies and care programs.
  • "Individualized assessment of neuroanatomical landmarks and cognitive skills is paramount for developing effective intervention strategies," commented Heidelberg University's Head of Neuroanatomy, Prof. Dr. Thomas Skutella.
  • Established in 1386, Heidelberg University is Germany's oldest university and a renowned research powerhouse in Stem Cell Research & Immunology in Europe.
  • With 56 Nobel Laureates associated with the institution, Heidelberg University boasts an illustrious history.

Surgalign Announces Release of HOLO™ AI Insights for Neurovascular Research

Retrieved on: 
月曜日, 5月 8, 2023
Spine, University, Population health, Workflow, Stroke, Brain, University of Pittsburgh School of Medicine, Perelman School of Medicine at the University of Pennsylvania, Science, MRI, Neuroanatomy, Neurosurgery, MD, Cooper University Hospital, Faculty, Artificial intelligence, Temple University School of Medicine, CT scan, AI, Notre Dame, Health, Wilfrid Sellars, Hospital, Medical device

HOLO AI, Surgalign’s portfolio of AI technology, utilizes convolutional neural network technology to automatically segment medical images, measure anatomic structures, automate pedicle screw planning, and perform other tasks.

Key Points: 
  • HOLO AI, Surgalign’s portfolio of AI technology, utilizes convolutional neural network technology to automatically segment medical images, measure anatomic structures, automate pedicle screw planning, and perform other tasks.
  • With this latest release, HOLO AI Insights has evolved to now address neurovascular research.
  • The insights generated by these results are believed to have multiple applications in population health, clinical research, and in the future, patient care.
  • Surgalign has partnered with Dr. Brian Jankowitz, a fellowship trained cerebrovascular neurosurgeon, for neurovascular research with HOLO AI Insights.

ALLEN INSTITUTE'S HONGKUI ZENG, PH.D., RECEIVES PRESTIGIOUS PRADEL RESEARCH AWARD FROM NATIONAL ACADEMY OF SCIENCES FOR PIONEERING WORK IN NEUROSCIENCE

Retrieved on: 
月曜日, 1月 23, 2023
Cortex, Neuroanatomy, Brandeis University, National Academy of Sciences, Cell, Neuron, Learning, Cell biology, Allen Institute, Nervous system, Allen Institute for Brain Science, Massachusetts Institute of Technology School of Science, Brain, Memory, Allen, Executive, Gene expression, National academy, Massachusetts Institute of Technology, Research, Management, Medical imaging, Doctor of Philosophy, Science

SEATTLE, Jan. 23, 2023 /PRNewswire/ -- The National Academy of Sciences has awarded Hongkui Zeng, Ph.D., with the 2023 Pradel Research Award for her seminal work in deepening science's understanding of cell types and connections in the mammalian brain and leading the development of neuroscience tools and open data resources that catalyze global research. The Pradel Research Award recognizes major contributions to our understanding of the nervous system. Zeng is the Executive Vice President and Director of the Allen Institute for Brain Science, a division of the Allen Institute, and a leading expert in molecular neuroscience, cell type diversity, and neuroanatomy.

Key Points: 
  • The Pradel Research Award recognizes major contributions to our understanding of the nervous system.
  • For more than 16 years, Hongkui, Ph.D., has been dedicated to deciphering the mysteries of the brain.
  • "I am deeply honored to receive this distinguished award from the National Academy of Sciences.
  • "I feel deeply indebted to my Allen Institute colleagues and our founders for doing extraordinary research together and making everything possible."

Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration

Retrieved on: 
火曜日, 11月 29, 2022
Health, Neurology, General Health, Research, Science, Pharmaceutical, Biotechnology, Allen Institute for Brain Science, Neurodegeneration, Science, Partner (business rank), Translation (biology), Genetics, Professor, Columbia University, Hospital, University, Genomics, Bristol Myers Squibb, Cajal, Brain, Biotechnology, Washington University School of Medicine, MBA, Factor H, CHDI Foundation, Patient, University of Washington Department of Bioengineering, Computational biology, Investment, Disease, Drug development, Lux Capital, Terra Venture Partners, Biochemistry, Baylor College of Medicine, Therapy, Neuroanatomy, HHMI, Allen Institute, Drug discovery, Massachusetts Institute of Technology, Pharmaceutical industry, Medical imaging, Management, Pediatrics, Neuroscience, Neurology

“The legendary neuroscientist Santiago Ramón y Cajal said that all outstanding work, in art as well as science, results from immense zeal applied to a great idea. That’s precisely why we raced to fund this team,” said Josh Wolfe, Co-founder and Managing Partner at Lux Capital. “When you get the rare combination of the leading scientific minds in neuroscience teaming up to work with cutting-edge visualization, sequencing and computational techniques, and to apply a never-before taken approach to discovering targets and drugs for neurodegenerative disease, you don’t walk slowly toward it -- you sprint for your life.”

Key Points: 
  • Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput functional validation.
  • Weve all seen the challenges that face drug discovery in neurodegeneration.
  • I truly believe our approach can revolutionize neurodegeneration drug discovery by understanding disease mechanisms with spatial and temporal resolution at unprecedented scale, said Ignacio Muoz-Sanjun, Ph.D., Chief Executive Officer at Cajal.
  • Cajal combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics and advanced microscopy, to accelerate neurodegeneration target and drug discovery.

FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer

Retrieved on: 
木曜日, 9月 15, 2022
National, Retinitis pigmentosa, Health, IPSC, National Center for Advancing Translational Sciences, Molecular biology, Gene editing, Potency (pharmacology), Knowledge, Cellular Dynamics International, Fujifilm, Patient, Sanford Burnham Prebys Medical Discovery Institute, Technology, NCATS, Quality of life, CDMO, Degenerative disease, University, Research, GLOBE, Neuroanatomy, Drug discovery, NIH, Pfizer, Mobile phone, Pharmaceutical industry, Innovation

MADISON, Wis., Sept. 15, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singe, M.D., as chief scientific officer effective September 12.

Key Points: 
  • MADISON, Wis., Sept. 15, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singe, M.D., as chief scientific officer effective September 12.
  • We are thrilled to welcome Dr. Singe to the FUJIFILM Cellular Dynamics family, said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics, Inc. Dr. Singe brings over 20 years of experience in cell and molecular biology, and extensive stem cell expertise, which will be instrumental as FUJIFILM Cellular Dynamics expands our application of leading-edge iPSC technologies to continue innovating in this field.
  • Prior to joining FUJIFILM Cellular Dynamics, Dr. Singe served as the inaugural director of the Stem Cell Translation Laboratory (SCTL) at the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH).
  • FUJIFILM Cellular Dynamics is a pioneer in developing iPSC technology for scientific and translational research, said Dr. Singe.